Talphera

Mr. Adams has chaired the Talphera Board of Directors since February 2013. He has chaired the boards of Impel NeuroPharma, Inc. since January 2020 and Akebia Therapeutics, Inc. since December 2018, and became Impel NeuroPharma's chief executive officer in May 2020.

Prior to joining Talphera, Mr. Dasu served as Vice President of Medical Device Engineering at Anesiva, Inc., and as Vice President of Manufacturing and Device Development at AlgoRx Pharmaceuticals, Inc., a pain management company that merged with Corgentech, Inc., in December 2005.

Ms. Broadfoot has served as chief financial officer of aTyr Pharma, Inc. since July 2018. From January 2017 to July 2018, she was chief financial officer of Emerald Health Pharmaceuticals Inc. and Emerald Health Bioceuticals Inc.

Ms. Bozilenko has served as a director of the company since March 2021 and has more than 30 years of investment banking and healthcare industry experience. Since June 2021, she has served as president and chief executive officer of Biothea Pharma, Inc.

Talphera is developing Niyad, nafamostat, for renal replacement therapy in dialysis patients who cannot tolerate heparin or have an increased risk of bleeding

Talphera's privacy policy describes information that may be collected from site users.

The site says its information is for general informational and educational purposes.

Talphera reports its **NEPHRO CRRT** clinical trial for **nafamostat** is **75% enrolled**, with completion expected in 2026. The **Draft 2026 KDIGO guidelines** now include nafamostat as an acceptable option for **continuous renal replacement therapy (CRRT)**. The company provides a corporate update alongside its second-quarter financial results.

Aug 2026PR NewswireNews article

Talphera reports its first-quarter 2026 financial results and delivers a corporate update. The specialty pharmaceutical company highlights progress in its pipeline of innovative treatments targeting rare and underserved diseases. Talphera continues to advance its commercialization efforts while maintaining focus on research and development initiatives.

May 2026PR NewswireNews article

TalPhera completes 50% enrollment for its NEPHRO CRRT clinical study and secures a $4.1 million financing tranche. The milestone follows earlier progress in patient recruitment for the trial. The company continues advancing its critical care research and development efforts.

Mar 2026TalpheraNews article

Talphera secures a $17 million first tranche financing deal, with strategic investor CorMedix, Inc. leading the round. The company updates stakeholders on its third-quarter 2025 financial performance and operational progress. This funding follows continued growth in its core business areas.

Nov 2025TalpheraNews article